LONDON, March 29,
2022 /PRNewswire/ -- Hikma Pharmaceuticals PLC
(Hikma), the multinational pharmaceutical company, announces that
its venture capital arm, Hikma Ventures has invested in Tact.ai,
the customer engagement company for life sciences. Tact.ai helps
pharmaceutical companies work more effectively with health care
professionals (HCPs) to deliver innovative medicines to patients
faster. The investment is the fourth Life Sciences industry
investment in the past six months for Tact.ai, following its
$33 million USD fundraise last
year.
Founded by former Salesforce.com executive, Chuck
Ganapathi, Tact's customer engagement platform is designed for life
sciences companies to take a holistic, outcome-centric approach to
how they engage customers across all channels: face-to-face, phone,
email, video, chat, and self-service. The platform innovations in
mobile, artificial intelligence (AI) and user experience – which
have been awarded six patents – enable field teams to boost
productivity, personalize every interaction, allow HCPs to engage
them on-demand and deliver a total experience to customers. The
platform integrates multiple systems of record like CRM, email,
calendar, next-best-action and 3rd party data into a unified system
of engagement so teams get more out of existing technologies while
creating better ways to work with the customer at every
touchpoint.
"Systems-of-record like CRM alone are no longer sufficient in
meeting the needs of today's commercial and medical leaders," said
Chuck Ganapathi, Founder and CEO of
Tact.ai. "We built a platform that gets the most out of existing
technology investments and puts the knowledge of the customer's
needs in the palm of every team member's hand so they can focus
more on educating and building trusted relationships. We're
thrilled to have Hikma Ventures join our journey to reimagine
customer engagement."
"There is a growing need within the life sciences industry for
hybrid engagement with health care providers and organizations,
especially in light of the global pandemic, and the Tact
platform provides a forward-thinking model for meeting that
demand," said Lana Ghanem, Managing
Director of Hikma Ventures. "By offering a secure and seamless user
experience that enables field teams to personalize each interaction
with their customers and capture more insights, Tact is helping
commercial and medical teams orchestrate the type of high-quality
engagement that customers demand today. We're impressed by Tact's
team experience and are excited to add it to our portfolio."
Tact.ai will use the proceeds to support further expansion with
leading pharma companies and to continue building the industry's
most customer-friendly engagement platform.
Investor
Enquiries:
|
|
Hikma
Ventures
Lana
Ghanem Managing Director, Hikma
Ventures
|
ana@hikmaventures.com
+962 6 580
3100
|
|
|
Media:
|
|
Steve
Weiss David
Belian US Communications and
Public Affairs
|
+1 732 788
8279
+1 848 254
4875
uscommunications@hikma.com
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions
of people around the world. For more than 40 years, we've been
creating high-quality medicines and making them accessible to the
people who need them. Headquartered in the UK, we are a global
company with a local presence across the
United States (US), the Middle
East and North Africa
(MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,700 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
About Hikma Ventures
Founded in August 2015, Hikma Ventures operates
as the corporate venture capital arm of Hikma
Pharmaceuticals. Hikma Ventures invests in
global start-ups where Hikma's expertise can
accelerate revenue growth and enhance value creation by providing
ventures with access to the resources of a multinational
pharmaceutical company. For more information, please visit
www.hikmaventures.com.
About Tact.ai
Tact.ai is on a mission to help life
science organizations nurture meaningful customer engagement
through our human-friendly software. Their AI-powered engagement
platform empowers field teams to work with their customers in new
ways to drive better outcomes. Tact.ai is headquartered in Silicon
Valley and is backed by some of the world's leading firms in
venture capital, technology, and healthcare and life sciences,
including Microsoft's venture fund M12, Salesforce Ventures,
Novartis, Lilly and McKesson Ventures. For more
information, please visit https://www.tact.ai/
View original
content:https://www.prnewswire.com/news-releases/hikma-ventures-invests-in-tactai-an-ai-powered-customer-engagement-platform-for-life-sciences-companies-301512365.html
SOURCE Hikma Pharmaceuticals USA Inc.